EEEda Eyduran

Eda Eyduran

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Eda Eyduran has a total of 58 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    From Heparin to Bivalirudin: The Unresolved Question of Optimal Dosing in Pediatric Extracorporeal Support

    by Ayşen Durak Aslan, Hamdi Cücan, Merve Havan, Eda Eyduran, Tanıl Kendirli

    Scientific Letter · Turkish Archives of Pediatrics, Early View

  • Open Access

    Factors Affecting Tacrolimus Levels in Pediatric Liver Transplant Recipients During the Early Posttransplant Period

    by Eda Eyduran, Ayşen Durak Aslan, Merve Havan, Arzu Meltem Demir, Ceyda Tuna Kırsaçlıoğlu, Zarife Kuloğlu, Aydan Kansu, Elvan Onur Kırımker, Meltem Koloğlu, Erdinç Devrim, et al.

    Background: Tacrolimus is the cornerstone of immunosuppression in pediatric liver transplantation (LT) but exhibits high pharmacokinetic variability. Objective: This study aimed to identify clinical and laboratory determinants of tacrolimus trough levels (C0) during the initial 14 days posttransplant. Methods: This retrospective study analyzed pediatric LT recipients (January 2020-October 2025). We evaluated continuous variables for normality using the Shapiro–Wilk test and analyzed them with nonparametric bivariate tests, including Spearman’s rank correlation and Mann-Whitney U tests. To account for repeated measurements within individual patients, we fitted a linear mixed-effects model with a random intercept. Backward elimination with a conservative threshold of p > 0.50 was applied to remove nonsignificant variables, while retaining predefined clinical covariates. Model fit was evaluated using Akaike Information Criterion (AIC) and Bayesian Information Criterion (BIC), and the final parsimonious model was selected by minimizing BIC while excluding individual antimicrobial treatments to prevent overfitting. To quantify complex polypharmacy and avoid overfitting, we created a Pharmacological Interaction Score (PIS) by assigning weighted positive or negative values to co-administered medications based on their known CYP3A4/5 inhibitory or inducing effects on tacrolimus. Results: In 33 patients, hemoglobin (β = 0.78, P < .001) and serum creatinine (β = 3.41, P < .001) were positively associated with tacrolimus levels, while INR showed a negative association (β = −1.00, P = .036). The model included albumin, a pharmacologic interaction score designed to simplify complex polypharmacy into a single numerical value, as well as platelet counts, which were retained but not statistically significant. Tacrolimus levels were not significantly influenced by sepsis, nutrition (enteral/parenteral), or extracorporeal therapies. Conclusion and Relevance: In this cohort, clinical complications such as sepsis, nutritional support methods, and extracorporeal therapies did not significantly affect drug trough levels. These results suggest that early postoperative fluctuations in whole-blood tacrolimus levels are mainly driven by patient hematological status, renal function, and graft recovery. Clinically, including hematological and biochemical parameters in routine drug monitoring could improve dose management and help prevent unnecessary empirical changes during critical care.

  • Intraoperative Continuous Kidney Replacement Therapy With Regional Epoprostenol Anticoagulation During Liver Transplantation in a Child With Severe Gastrointestinal Bleeding

    by Eda Eyduran, Duygu İyI, Ayşen Durak Aslan, Ulkar Huseyinova, Merve Havan, Tanıl Kendirli

    Background: Acute kidney injury (AKI) is a significant complication in pediatric liver transplant (LT) patients. This is often exacerbated by liver dysfunction, fluid overload, and metabolic disturbances. Intraoperative continuous kidney replacement therapy (IO‐CKRT) is an emerging strategy to manage these complex patients, aiming to stabilize fluid, electrolyte, and acid–base imbalances. Epoprostenol is utilized as an anticoagulant during CKRT to maintain circuit patency, particularly in patients at high risk of bleeding by inhibiting platelet aggregation. However, the use of IO‐CKRT with epoprostenol specifically in pediatric LT recipients is poorly documented. Methods: We present a case of a 12 year‐old girl with biliary atresia and cirrhosis who underwent urgent LT from a deceased donor. She developed hemorrhagic shock and multi‐organ failure, necessitating pre‐transplant plasmapheresis and subsequent CKRT with epoprostenol. IO‐CKRT was maintained during the 12 h LT to manage acid–base balance, electrolyte levels, and volume status. Results: Despite epoprostenol anticoagulation for hemofiltration, no abnormal bleeding occurred in the gastrointestinal or surgical areas during transplantation. Post‐transplantation, the patient's inotropic support requirements decreased within 24 h. Conclusions: IO‐CKRT effectively achieves fluid and metabolic balance during LT in pediatric patients with AKI, fluid overload, and metabolic issues. Epoprostenol proves to be a safe and effective regional anticoagulation option for CKRT in bleeding patients undergoing LT, preventing site bleeding without systemic complications. This case highlights a unique and important application that warrants further investigation into its broader effectiveness and potential complications in this vulnerable patient population.

  • Continuous Renal Replacement Therapy for Acute Decompensation in Inborn Errors of Metabolism: Single-Center, Pediatric Cohort, 2014–2025

    by Merve Setenay Akyüzlüer Güneş, Engin Köse, Eda Eyduran, Doğan Kaymaz, Leyla Kaya, Merve Havan, Emel Okulu, Tanil Kendirli, Fatma Tuba Eminoğlu

    Objectives: To review our use and outcomes of continuous renal replacement therapy (CRRT) for acute metabolic decompensation (hyperammonemia or hyperleucinemia) in infants and children with inborn errors of metabolism (i.e., M), and to identify factors associated with complications and mortality. Design: Retrospective cohort identified using local clinical databases. Setting: Single-center PICU and neonatal ICU in a tertiary pediatric center in Türkiye. Patients: Thirty-eight children (with 49 CRRT sessions) for urea cycle disorders, organic acidemias, or maple syrup urine disease undergoing treatment between August 2014 and June 2025. Interventions: None. Measurements and Main Results: The median (interquartile range, IQR) age at CRRT initiation was 1.4 months (IQR 0.16–33.90); CRRT resulted in substantial metabolite reduction (mean change 87.6% for ammonia and 74.8% for leucine). Younger age was associated with more hemodynamic and metabolic complications. Overall mortality was 11 of 38 (28.9% [95% CI, 17–44.8%]). In the 11 episodes of CRRT that ended in death vs. 38 CRRT episodes with survival to discharge, there was a greater proportion with hypophosphatemia: 6 of 11 vs. 8 of 38, percentage difference 33.4% (95% CI, 2.8–59.6%), p value of equals to 0.03. Last, we failed to identify an association between episodes of CRRT by technique (continuous venovenous hemodiafiltration [CVVHDF] vs. dialysis) and mortality: 6 of 21 vs. 5 of 28, mean difference 10.7% (95% CI, –12.4 to 34.3%), p value of equal to 0.38. Conclusions: In our single-center 11-year experience of using CRRT for metabolic detoxification in critically ill young infants with inborn errors of metabolism, we have found that substantial reductions in ammonia and leucine can be achieved in severe biochemical derangement, irrespective of whether continuous venovenous hemodialysis or CVVHDF was used. Taken together, for us, these findings reinforce our continued practice of timely CRRT as a critical component of acute metabolic crisis management.

  • Extracorporeal Membrane Oxygenation in Pediatric Patients

    by Ayşen Durak Aslan, Eda Eyduran, Merve Havan, Tanıl Kendirli

    The primary goal of extracorporeal membrane oxygenation (ECMO) is to provide time for the effective treatment of the underlying disease; it does not directly treat the disease itself but serves as a bridge to recovery or to definitive therapies such as heart or lung transplantation. This review article aims to examine the fundamental components and various cannulation strategies of ECMO in pediatric patients, as well as its indications, anticoagulation strategies, and potential complications.

  • Open Access

    Ceftazidime–avibactam for multidrug and pandrug-resistant gram-negative infections in critically Ill children: a single-center pediatric ıntensive care experience

    by Merve Havan, Gül Arga, Yunus Emre Bülbül, Burak Özerdem, Eda Eyduran, Ayşen Durak Aslan, Nilay Penezoğlu, Hatice Belkıs İnceli, Duygu Öcal, Halil Özdemir, et al.

    Carbapenem-resistant multidrug-resistant (MDR) and pandrug-resistant (PDR) Gram-negative infections represent a critical therapeutic challenge in pediatric intensive care units (PICUs), where effective treatment options are extremely limited. This study aimed to describe the real-world clinical outcomes and safety of ceftazidime–avibactam (CZA) in critically ill children with MDR/PDR infections. We conducted a retrospective observational study of pediatric patients aged 1 month to 18 years who received CZA for microbiologically confirmed MDR or PDR Gram-negative infections in a tertiary PICU between February 2021 and January 2025. Twenty-one critically ill children (median age 55 months, IQR 11–126) were included; two-thirds had underlying chronic conditions and 23.8% were immunosuppressed. Klebsiella pneumoniae was the predominant pathogen (85.7%). Microbiological clearance in follow-up cultures was observed in 85.7% of patients with available microbiological data, and clinical improvement was noted in most patients in this critically ill population. Infection-related mortality was 19% and was primarily associated with host-related factors, including younger age and immunosuppression. Resistance emergence during therapy was observed in one patient. Such resistance development during CZA treatment has been reported rarely in the literature and may involve mechanisms such as mutations in carbapenemase enzymes or alterations in bacterial permeability. In our study, resistance was detected during ongoing therapy in a single patient with Klebsiella pneumoniae , highlighting the importance of close microbiological monitoring in critically ill patients receiving prolonged treatment. Conclusion : CZA was used as a salvage treatment in critically ill children with MDR and PDR Gram-negative infections, with favorable clinical and microbiological outcomes observed. These real-world data support its cautious incorporation into pediatric antimicrobial stewardship strategies in PICU settings. What is Known: • Ceftazidime–avibactam is a promising agent against carbapenem-resistant Enterobacterales in adults. • Pediatric data remain limited, especially in critically ill children with MDR or PDR infections. What is New: • Ceftazidime–avibactam was used as salvage therapy for multidrug- and pandrug-resistant Gram-negative infections in critically ill children. • Clinical and microbiological response was achieved in a high-risk PICU population despite prolonged hospitalization and extensive prior antibiotic exposure.


  • The Cases of Acute Necrotizing Encephalopathy Due to Human Herpes Virus-6

    by İzEl Yilmaz, Eda Eyduran, Ayşen Durak Aslan, Merve Havan, Belkis Hatice İnCeli, Halil Özdemir, Fatma Pinar Tabanli, Miraç Yildirim, Tanil Kendirli

    Background: Human herpesvirus-6 (HHV-6) is a neurotropic virus that typically remains latent in immunocompetent individuals but may cause severe neurologic complications, including encephalitis, particularly in immunocompromised hosts. Rarely, HHV-6 encephalitis can also occur in immunocompetent children, often presenting with features of acute necrotizing encephalopathy. Cases: We report 2 cases of previously healthy toddlers who presented with fever, seizures and altered mental status. Neuroimaging revealed bilateral thalamic involvement consistent with acute necrotizing encephalopathy. HHV-6 DNA was detected in cerebrospinal fluid via polymerase chain reaction, confirming the diagnosis. Both patients received antiviral therapy with foscarnet, alongside immunomodulatory treatments including intravenous immunoglobulin, corticosteroids, plasmapheresis and, in 1 case, tocilizumab. Clinical outcomes varied, with 1 patient achieving full recovery and the other showing partial neurologic improvement. Conclusions: These cases highlight the potential for HHV-6 to cause severe encephalopathy in immunocompetent children. Early recognition, neuroimaging, and cerebrospinal fluid polymerase chain reaction testing are essential for diagnosis. Combined antiviral and immunomodulatory therapies may improve outcomes by addressing both viral replication and neuroinflammation.


  • Management of a Child With Hypersplenism During the Peritransplantation Period Should Splenectomy Be Performed Before or During the Liver Transplantation?

    by Eda Eyduran, Aysen Durak Aslan, Merve Havan, Zarife Kuloglu, Ozlem Selvi Can, Omer Suat Fitoz, Elvan Onur Kirimker, Meltem Kologlu, Tanil Kendirli

    Background: Biliary atresia (BA) is the most common cause of liver transplantation (LT) in children. Despite a successful Kasai procedure, liver cirrhosis develops in half of the patients in the first 2 years of life. Hypersplenism secondary to cirrhosis causes cytopenias, immune dysregulation, and increased intra‐abdominal pressure. LT reduces hypersplenism complications due to normalized portal pressure. In cases with normal liver function but severe hypersplenism, interventions are needed before or simultaneous with LT, despite the possible negative effects of splenic interventions on graft perfusion and, thus, function. Methods: Here, we present a 23‐month‐old boy with BA and hypersplenism symptoms despite a normally functional liver. Using cases from the literature, we discussed the advantages and disadvantages of hypersplenism management in the peritransplantation period with our patient. Results: Interventions like splenectomy and splenic artery ligation (SAL) to reduce hypersplenism‐related complications can be performed in the pre‐ and/or post‐transplantation period. Conclusions: Necessary interventions should be personalized for each patient according to their clinical conditions and possible issues.

  • Open Access

    Successfully Treated Adenovirus-Associated Fulminant Myocarditis by Cidofovir

    by Ayşen Durak Aslan, Merve Havan, Gül Arga, Eda Eyduran, Tayfun Uçar, Tanıl Kendirli

    Cite this article as: Aslan AD, Havan M, Arga G, Eyduran E, Uçar T, Kendirli T. Successfully treated adenovirus-associated fulminant myocarditis by cidofovir. Turk Arch Pediatr. 2025;60(6):683-684.